Related Experiment Video
Updated: Aug 17, 2026
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
[Multiple sclerosis therapy]
1Neuroloska klinika, Klinicki centar Univerziteta u Sarajevu.
Abstract:
Although still with the unclear etiology, multiple sclerosis (MS) is, according to the majority of researchers, autoimmune disease which affects people with the genetic predisposition. This is illness of the white mass of the brain and spinal cord which is causing damage to the myelin, but also to the degeneration of the axons, with the accompanying inflammatory reaction. Clinical course of the illness is characterized by wide distribution in time and space. It is more common among women than man (in some cases that ratio could be (3:1), among white than black, and it shows different geographical distribution. It is most frequent at the age from 20 to 40 years, but it is not uncommon in younger and older ages. Related to its still unknown ethiology the therapy in best case is imunomodulational or immunosuppressive, but in the majority of cases symptolmatological. After all of this question occurred: WHEN AND WHICH THERAPY WE SHOULD USE FOR THE PATIENTS?
Insights
Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system, with unknown causes but genetic links. Research is ongoing to determine optimal timing and types of therapies for MS patients.
Area of Science:
- Neuroimmunology
- Genetics
- Epidemiology
Context:
- Multiple sclerosis (MS) is a chronic autoimmune disease impacting the central nervous system.
- It involves myelin and axonal damage, with inflammation, in genetically predisposed individuals.
- MS exhibits varied clinical courses, demographics, and geographical distributions.
Purpose:
- To explore the autoimmune basis of MS.
- To understand the demographic and geographical variations in MS.
- To address the critical question of when and which therapies to employ for MS patients, given the current treatment limitations.
Summary:
- MS is characterized by demyelination and axonal degeneration in the brain and spinal cord.
- The disease predominantly affects women and has a specific age distribution (20-40 years).
- Current therapies are primarily immunomodulatory, immunosuppressive, or symptomatic, highlighting a need for optimized treatment strategies.
Impact:
- Understanding MS etiology and progression is crucial for developing targeted treatments.
- Identifying risk factors and disease patterns can aid in early diagnosis and management.
- This research underscores the need for evidence-based guidelines on therapeutic interventions in MS care.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:22Alzheimer's Disease: Treatment
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...